Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05774080 · ClinicalTrials.gov registry record
An Observational Study of Patients With Chronic Gastrointestinal Disease
A clinical trial of Gastrointestinal Diseases, sponsored by Target PharmaSolutions.
- Active
- Registry status
- 500,000
- Enrollment target
- 1
- Study location
NCT05774080: Active study of Gastrointestinal Diseases, sponsored by Target PharmaSolutions.
NCT05774080 is a study of Gastrointestinal Diseases that is active but no longer recruiting, run by Target PharmaSolutions. The registered enrollment target is 500,000 participants, above the 703-participant average among 14 other Gastrointestinal Diseases trials with a reported enrollment target (71024% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05774080, a study of Gastrointestinal Diseases, is active but no longer recruiting, sponsored by Target PharmaSolutions.
- ACTIVE NOT RECRUITING
- Registry status
- 500,000 participants
- Enrollment target
- 1
- Study location
Study Summary
TARGET-GASTRO is an observational research study to conduct a comprehensive review of outcomes for patients with the chronic gastrointestinal (GI) diseases: eosinophilic gastrointestinal disease (EGID), ulcerative colitis (UC) or Crohn's disease (CD).
Conditions Studied
Interventions
- OTHER Observational
Study Locations (1)
North Carolina
- Atrium Health/Wake Forest University School of Medicine - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500,000 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2037-12 |
What the registry record for NCT05774080 still lists
NCT05774080 is an observational study that tracks outcomes without assigning an intervention. Its 500,000 participants enrollment target places it among the larger protocols in the corpus, above the 703-participant average among 14 other Gastrointestinal Diseases trials with a reported enrollment target (71024% higher).
The record links to 1 condition, with Gastrointestinal Diseases appearing as the primary indexed condition, and to 1 intervention - of which Observational is the first listed.
NCT05774080 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05774080 about?
NCT05774080 is a clinical study titled "An Observational Study of Patients With Chronic Gastrointestinal Disease". TARGET-GASTRO is an observational research study to conduct a comprehensive review of outcomes for patients with the chronic gastrointestinal (GI) diseases: eosinophilic gastrointestinal disease (EGID), ulcerative colitis (UC) or Crohn's disease (CD).
What is the current status of trial NCT05774080?
This trial is currently active not recruiting. The enrollment target is 500,000 participants. The study started on 2023-08-01. Estimated completion is 2037-12.
What conditions does trial NCT05774080 study?
This clinical trial studies the following conditions: Gastrointestinal Diseases.
What interventions are being tested in trial NCT05774080?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT05774080?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05774080 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05774080's enrollment target sits among peer trials
500,000 1st of 14 higher than 14 of 14 other Gastrointestinal Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
Foregut Leaks-Role of Microbiome
RECRUITING · NA
-
Trans-nasal Endoscopy for Bariatric Patients
RECRUITING · NA
-
Evaluation of Patients With Gastrointestinal Disease
RECRUITING
-
Virtual Reality for Non-cardiac Chest Pain
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065060 · 500,000 participants
Parkinson Progression Marker Initiative Online (PPMI Online)
- NCT06017687 · 500,000 participants · NA
Data Collection and Evaluation of OptiBP Under Investigational Use
- NCT06342375 · 425,000 participants · NA
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage
- NCT06934239 · 400,000 participants · Phase 4
A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI